세계의 흡입식 일산화질소 시장 규모 조사 : 용도별, 지역별 예측(2022-2032년)

Global Inhaled Nitric Oxide Market is valued approximately at USD 1.12 billion in 2023 and is anticipated to grow with a healthy growth rate of more than 7.70% over the forecast period 2024-2032. Inhaled nitric oxide (iNO) is a medical gas used as a therapeutic agent to improve oxygenation in individuals facing certain respiratory difficulties. It works by expanding blood vessels in the lungs, promoting better blood flow to areas essential for effective oxygen exchange. Nitric oxide is a naturally produced molecule in the body, playing a role in vasodilation and regulating blood pressure. . iNO targets blood vessels surrounding oxygen-rich areas in the lungs, promoting relaxation and heightened blood flow to facilitate optimal oxygen uptake by red blood cells. This targeted action is essential in treating conditions such as neonatal respiratory treatment, chronic obstructive pulmonary disease, acute respiratory distress syndrome, others. Accordingly, iNO plays a vital role in managing vascular and oxygenation issues, especially in neonatal and critical care scenarios. The robust clinical evidence supporting the efficacy and safety of iNO therapy in adults is a key trend supporting the growth of the Global Inhaled Nitric Oxide Market.

The growth of the inhaled nitric oxide market is anticipated to surge significantly due to increased adoption for managing pulmonary disorders in infants and newborns, coupled with a rise in respiratory disorders prevalence and advancements in healthcare infrastructure. Also, there is growing awareness regarding inhaled nitric oxide's effectiveness in treating various pulmonary conditions, especially in neonates, which is supporting the market expansion during the estimated period of 2024-2032. For instance, a 2022 article from the National Heart, Lung, and Blood Institute highlights the range of breathing problems affecting newborns, including transient tachypnea, neonatal respiratory distress syndrome (RDS), persistent pulmonary hypertension of the newborn (PPHN), meconium aspiration syndrome, and bronchopulmonary dysplasia (BPD). PPHN is a critical condition marked by heightened pulmonary vascular resistance is a primary indication for inhaled nitric oxide therapy. Its mechanism involves selective dilation of pulmonary blood vessels, enhancing oxygenation, and reducing reliance on invasive ventilation methods. Furthermore, the U.S. Food and Drug Administration's approval for inhaled nitric oxide in treating hypoxic respiratory failure further bolsters its adoption. Consequently, the surge in adoption of inhaled nitric oxide in order to manage respiratory complications in newborns is poised to drive the projected growth of the inhaled nitric oxide market. Furthermore, intensive research and development activities focused on inhaled nitric oxide are anticipated to present substantial growth opportunities within the market for this therapeutic gas. Inhaled nitric oxide has attracted considerable interest due to its promising therapeutic potential across a spectrum of pulmonary and cardiovascular conditions. The ongoing progress in medical science and technology has spurred investigations into innovative applications and formulations of inhaled nitric oxide, prompting heightened investments in research and development by pharmaceutical firms and research establishments. These initiatives aim to refine delivery mechanisms, dosage protocols, and broaden the scope of indications for inhaled nitric oxide therapy. However, stringent application norms across various regions, along with high costs incurred with the procedure is expected to hinder the market growth between 2022 and 2032.

The key regions considered for the global Inhaled Nitric Oxide Market study includes Asia Pacific, North America, Europe, Latin America, and Rest of the World. In 2023, North America is a dominating region in the inhaled nitric oxide market and is projected to sustain its leading position with the highest number of market shares throughout the forecast period. Key factors such as presence of advanced healthcare facilities and substantial healthcare expenditure levels that facilitate the adoption of innovative treatments like inhaled nitric oxide are primarily bolstering the regional market growth. Moreover, North America benefits from extensive research and development initiatives, coupled with a favorable regulatory landscape, which have fostered the advancement and commercial availability of inhaled nitric oxide products in the region. Whereas, the market in Asia Pacific is anticipated to grow at the fastest rate over the forecast period owing to the rising prevalence of respiratory conditions such as chronic obstructive pulmonary disease (COPD), pulmonary hypertension, and neonatal hypoxic respiratory failure.

Major market player included in this report are:

• Air Liquide Healthcare (France)
• SOL Group (Italy)
• Matheson Tri-Gas Inc. (United States)
• Merck KGaA (Germany)
• Mallinckrodt Pharmaceuticals (United Kingdom)
• Nu-Med Plus Inc. (United States)
• Perma Pure LLC (United States)
• Praxair Distribution Inc. (United States)
• HALMA PLC (United Kingdom)
• LINDE PLC (Germany)

The detailed segments and sub-segment of the market are explained below:

By Application

• Neonatal Respiratory Treatment
• Chronic Obstructive Pulmonary Disease
• Acute Respiratory Distress Syndrome
• Others

By Region:

• North America
• U.S.
• Canada
• Europe
• UK
• Germany
• France
• Spain
• Italy
• ROE
• Asia Pacific
• China
• India
• Japan
• Australia
• South Korea
• RoAPAC
• Latin America
• Brazil
• Mexico
• Middle East & Africa
• Saudi Arabia
• South Africa
• RoMEA

Years considered for the study are as follows:

• Historical year - 2022
• Base year - 2023
• Forecast period - 2024 to 2032

Key Takeaways:

• Market Estimates & Forecast for 10 years from 2022 to 2032.
• Annualized revenues and regional level analysis for each market segment.
• Detailed analysis of geographical landscape with Country level analysis of major regions.
• Competitive landscape with information on major players in the market.
• Analysis of key business strategies and recommendations on future market approach.
• Analysis of competitive structure of the market.
• Demand side and supply side analysis of the market.

Table of Contents

Chapter 1.Global Inhaled Nitric Oxide Market Definition and Research Assumptions

• 1.1.Research Objective
• 1.2.Market Definition
• 1.3.Research Assumptions
  • 1.3.1.Inclusion & Exclusion
  • 1.3.2.Limitations
  • 1.3.3.Supply Side Analysis
    • 1.3.3.1.Availability
    • 1.3.3.2.Infrastructure
    • 1.3.3.3.Regulatory Environment
    • 1.3.3.4.Market Competition
    • 1.3.3.5.Economic Viability (Consumer's Perspective)
  • 1.3.4.Demand Side Analysis
    • 1.3.4.1.Regulatory frameworks
    • 1.3.4.2.Technological Advancements
    • 1.3.4.3.Environmental Considerations
    • 1.3.4.4.Consumer Awareness & Acceptance
• 1.4.Estimation Methodology
• 1.5.Years Considered for the Study
• 1.6.Currency Conversion Rates

Chapter 2.Executive Summary

• 2.1.Global Inhaled Nitric Oxide Market Size & Forecast (2022- 2032)
• 2.2.Regional Summary
• 2.3.Segmental Summary
  • 2.3.1.By Application
• 2.4.Key Trends
• 2.5.Recession Impact
• 2.6.Analyst Recommendation & Conclusion

Chapter 3.Global Inhaled Nitric Oxide Market Dynamics

• 3.1.Market Drivers
• 3.2.Market Challenges
• 3.3.Market Opportunities

Chapter 4.Global Inhaled Nitric Oxide Market: Industry Analysis

• 4.1.Porter's 5 Force Model
  • 4.1.1.Bargaining Power of Suppliers
  • 4.1.2.Bargaining Power of Buyers
  • 4.1.3.Threat of New Entrants
  • 4.1.4.Threat of Substitutes
  • 4.1.5.Competitive Rivalry
  • 4.1.6.Futuristic Approach to Porter's 5 Force Model
  • 4.1.7.Porter's 5 Force Impact Analysis
• 4.2.PESTEL Analysis
  • 4.2.1.Political
  • 4.2.2.Economic
  • 4.2.3.Social
  • 4.2.4.Technological
  • 4.2.5.Environmental
  • 4.2.6.Legal
• 4.3.Top investment opportunity
• 4.4.Top winning strategies
• 4.5.Disruptive Trends
• 4.6.Industry Expert Perspective
• 4.7.Analyst Recommendation & Conclusion

Chapter 5.Global Inhaled Nitric Oxide Market Size & Forecasts by Application 2022-2032

• 5.1.Neonatal Respiratory Treatment
• 5.2.Chronic Obstructive Pulmonary Disease
• 5.3.Acute Respiratory Distress Syndrome
• 5.4.Others

Chapter 6.Global Inhaled Nitric Oxide Market Size & Forecasts by Region 2022-2032

• 6.1.North America Inhaled Nitric Oxide Market
  • 6.1.1.U.S. Inhaled Nitric Oxide Market
    • 6.1.1.1. Application breakdown size & forecasts, 2022-2032
  • 6.1.2.Canada Inhaled Nitric Oxide Market
• 6.2.Europe Inhaled Nitric Oxide Market
  • 6.2.1.U.K. Inhaled Nitric Oxide Market
  • 6.2.2.Germany Inhaled Nitric Oxide Market
  • 6.2.3.France Inhaled Nitric Oxide Market
  • 6.2.4.Spain Inhaled Nitric Oxide Market
  • 6.2.5.Italy Inhaled Nitric Oxide Market
  • 6.2.6.Rest of Europe Inhaled Nitric Oxide Market
• 6.3.Asia-Pacific Inhaled Nitric Oxide Market
  • 6.3.1.China Inhaled Nitric Oxide Market
  • 6.3.2.India Inhaled Nitric Oxide Market
  • 6.3.3.Japan Inhaled Nitric Oxide Market
  • 6.3.4.Australia Inhaled Nitric Oxide Market
  • 6.3.5.South Korea Inhaled Nitric Oxide Market
  • 6.3.6.Rest of Asia Pacific Inhaled Nitric Oxide Market
• 6.4.Latin America Inhaled Nitric Oxide Market
  • 6.4.1.Brazil Inhaled Nitric Oxide Market
  • 6.4.2.Mexico Inhaled Nitric Oxide Market
  • 6.4.3.Rest of Latin America Inhaled Nitric Oxide Market
• 6.5.Middle East & Africa Inhaled Nitric Oxide Market
  • 6.5.1. Saudi Arabia Inhaled Nitric Oxide Market
  • 6.5.2. South Africa Inhaled Nitric Oxide Market
  • 6.5.3.Rest of Middle East & Africa Inhaled Nitric Oxide Market

Chapter 7.Competitive Intelligence

• 7.1.Key Company SWOT Analysis
• 7.2.Top Market Strategies
• 7.3.Company Profiles
  • 7.3.1.Air Liquide Healthcare (France)
    • 7.3.1.1.Key Information
    • 7.3.1.2.Overview
    • 7.3.1.3.Financial (Subject to Data Availability)
    • 7.3.1.4.Product Summary
    • 7.3.1.5.Market Strategies
  • 7.3.2.SOL Group (Italy)
  • 7.3.3.Matheson Tri-Gas Inc. (United States)
  • 7.3.4.Merck KGaA (Germany)
  • 7.3.5.Mallinckrodt Pharmaceuticals (United Kingdom)
  • 7.3.6.Nu-Med Plus Inc. (United States)
  • 7.3.7.Perma Pure LLC (United States)
  • 7.3.8.Praxair Distribution Inc. (United States)
  • 7.3.9.HALMA PLC (United Kingdom)
  • 7.3.10.LINDE PLC (Germany)

Chapter 8.Research Process

• 8.1.Research Process
  • 8.1.1.Data Mining
  • 8.1.2.Analysis
  • 8.1.3.Market Estimation
  • 8.1.4.Validation
  • 8.1.5.Publishing
• 8.2.Research Attributes